Diagnostic chest radiation before 30 may increase breast cancer risk

September 6, 2012

Women carrying a mutation in the BRCA1- or BRCA2- genes (which control the suppression of breast and ovarian cancer) who have undergone diagnostic radiation to the chest before the age of 30 are more likely to develop breast cancer than those who carry the gene mutation but who have not been exposed, a study published in the British Medical Journal today reveals.

The BMJ published a commentary in August which argued that a charity was using misleading statistics to persuade women to undergo mammography, concluding that charities should stop generating false hope and that women need and deserve the facts instead.

Exposure to radiation is an established risk factor for breast cancer in the general population. Some studies have suggested that women with a mutated BRCA1/2 gene may have increased radiation sensitivity because BRCA1 and BRCA2 are the genes involved in the repair of , which can be caused by radiation. The benefit from mammographic screening in young BRCA1/2 mutation carriers may therefore not outweigh the . Some countries have even gone as far as recommending that women avoid mammographic screening before the age of 30 but results of studies have been inconsistent.

Authors from the Netherlands Cancer Institute therefore looked at 1993 female BRCA1/2 mutation carriers in the Netherlands, France and the UK between 2006 and 2009 to see whether variations in DNA increase the chances of radiation-induced breast cancer risk. Follow-up ended with diagnosis of first breast cancer. All patients were aged 18 or over.

Women were questioned on exposure via x-ray or mammogram, age at first exposure, number of exposures before age 20, at ages 20-29, 30-39 and age at last exposure.

Results showed that 43% (848) of the 1993 women were diagnosed with breast cancer. 48% (926) reported ever having an x-ray and 33% (637) a mammogram. The average age at first mammogram was 29 years. A history of any exposure to diagnostic or screening radiation to the chest at ages 20 to 29 increased breast cancer risk by 43% and any exposure before the age of 20 increased breast cancer risk by 62%. No association with breast cancer was apparent for exposures at ages 30-39.

For every 100 BRCA1/2 mutation carriers aged 30, nine will have developed breast cancer by the age of 40 and the number of cases would increase by five if all had had one mammogram before age 30. The authors do say however that this estimate "should be interpreted with caution because there were few women with breast cancer who had had a mammogram before age 30 in the study".

The authors conclude that "exposure to diagnostic radiation before age 30 was associated with an increased breast cancer risk in BRCA1/2 mutation carriers". They say however due to "puzzling" findings in the differences between for BRCA1 and BRCA2 carriers, larger studies are needed to determine whether a difference does in fact exist. The authors recommend non-ionizing radiation imaging techniques, such as MRI, for mutation carriers.

Explore further: Risk for developing new cancer in other breast increased for survivors with BRCA mutation

More information: Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK), British Medical Journal, 2012.

Related Stories

Risk for developing new cancer in other breast increased for survivors with BRCA mutation

December 8, 2011
Breast cancer survivors who carry the BRCA1 or BRCA2 genetic mutation are at high risk for developing contralateral breast cancer — a new primary tumor in the other breast — and certain women within this group of ...

After chest radiation, girls at greater risk for early breast cancer: study

June 4, 2012
(HealthDay) -- Girls who receive radiation to the chest to treat childhood cancer, even those getting lower doses, have a high risk of developing breast cancer at a young age, according to a new study.

Recommended for you

Team identifies a switch that may help target dormant cancer cells

September 26, 2017
A study by scientists at the University of Arizona and the University of Pittsburgh may hold the key to targeting dormant—or inactive —cancer cells, which are resistant to chemotherapy and other treatments. The results ...

Researchers discover how enzyme 'shape-shifts' in drug-resistant leukemia

September 26, 2017
St. Jude Children's Research Hospital structural biologists have deciphered how the structure of the enzyme called Abl regulates its activity, enabling the enzyme to switch itself on and off. Understanding Abl's regulation ...

Powerful drug combo gangs up to tackle triple-negative breast cancer

September 26, 2017
In the hunt for novel treatments against an aggressive form of breast cancer, researchers combined a new protein inhibitor with a chemotherapy drug to create a powerful combination that resulted in cancer cell death.

Researchers identify gene variants linked to a high-risk children's cancer

September 25, 2017
Pediatric researchers investigating the childhood cancer neuroblastoma have identified common gene variants that raise the risk of an aggressive form of that disease. The discovery may assist doctors in better diagnosing ...

MRI contrast agent locates and distinguishes aggressive from slow-growing breast cancer

September 25, 2017
A new magnetic resonance imaging (MRI) contrast agent being tested by researchers at Case Western Reserve University not only pinpoints breast cancers at early stages but differentiates between aggressive and slow-growing ...

Prostaglandin E1 inhibits leukemia stem cells

September 25, 2017
Two drugs, already approved for safe use in people, may be able to improve therapy for chronic myeloid leukemia (CML), a blood cancer that affects myeloid cells, according to results from a University of Iowa study in mice.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.